Back to search
Advanced Metastatic Castration-resistant Prostate Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Metastatic Castration-resistant Prostate Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Metastatic Castration-resistant Prostate Cancer trials you may qualify forThe goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused…
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prost…
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone,…
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Ef…
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how we…
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Par…
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization…